287 related articles for article (PubMed ID: 20525386)
1. Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma.
Bedin V; Adam RL; de Sá BC; Landman G; Metze K
BMC Cancer; 2010 Jun; 10():260. PubMed ID: 20525386
[TBL] [Abstract][Full Text] [Related]
2. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
4. Fractal characteristics of May-Grünwald-Giemsa stained chromatin are independent prognostic factors for survival in multiple myeloma.
Ferro DP; Falconi MA; Adam RL; Ortega MM; Lima CP; de Souza CA; Lorand-Metze I; Metze K
PLoS One; 2011; 6(6):e20706. PubMed ID: 21698234
[TBL] [Abstract][Full Text] [Related]
5. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin.
Talve LA; Collan YU; Ekfors TO
J Cutan Pathol; 1996 Aug; 23(4):335-43. PubMed ID: 8864921
[TBL] [Abstract][Full Text] [Related]
6. Fractal dimension of chromatin: potential molecular diagnostic applications for cancer prognosis.
Metze K
Expert Rev Mol Diagn; 2013 Sep; 13(7):719-35. PubMed ID: 24063399
[TBL] [Abstract][Full Text] [Related]
7. Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas.
Drabeni M; Lopez-Vilaró L; Barranco C; Trevisan G; Gallardo F; Pujol RM
Am J Dermatopathol; 2013 Feb; 35(1):56-63. PubMed ID: 22688397
[TBL] [Abstract][Full Text] [Related]
8. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
9. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
[TBL] [Abstract][Full Text] [Related]
10. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
11. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker.
Pacifico MD; Grover R; Richman PI; Daley FM; Buffa F; Wilson GD
Plast Reconstr Surg; 2005 Feb; 115(2):367-75. PubMed ID: 15692338
[TBL] [Abstract][Full Text] [Related]
12. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.
Thompson JF; Soong SJ; Balch CM; Gershenwald JE; Ding S; Coit DG; Flaherty KT; Gimotty PA; Johnson T; Johnson MM; Leong SP; Ross MI; Byrd DR; Cascinelli N; Cochran AJ; Eggermont AM; McMasters KM; Mihm MC; Morton DL; Sondak VK
J Clin Oncol; 2011 Jun; 29(16):2199-205. PubMed ID: 21519009
[TBL] [Abstract][Full Text] [Related]
14. Independent prognostic importance of vascular invasion in nodular melanomas.
Straume O; Akslen LA
Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
[TBL] [Abstract][Full Text] [Related]
15. Stereologic estimation of volume-weighted mean nuclear volume as a predictor of prognosis in "thin" malignant melanoma.
Binder M; Dolezal I; Wolff K; Pehamberger H
J Invest Dermatol; 1992 Aug; 99(2):180-3. PubMed ID: 1629630
[TBL] [Abstract][Full Text] [Related]
16. The fractal dimension of nuclear chromatin as a prognostic factor in acute precursor B lymphoblastic leukemia.
Adam RL; Silva RC; Pereira FG; Leite NJ; Lorand-Metze I; Metze K
Cell Oncol; 2006; 28(1-2):55-9. PubMed ID: 16675881
[TBL] [Abstract][Full Text] [Related]
17. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods.
Balch CM; Murad TM; Soong SJ; Ingalls AL; Halpern NB; Maddox WA
Ann Surg; 1978 Dec; 188(6):732-42. PubMed ID: 736651
[TBL] [Abstract][Full Text] [Related]
18. Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.
Karjalainen J; Eskelinen M; Kosma VM; Lipponen P; Tuominen L; Alhava E
Anticancer Res; 1992; 12(5):1507-11. PubMed ID: 1444213
[TBL] [Abstract][Full Text] [Related]
19. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression.
Massi D; Franchi A; Borgognoni L; Reali UM; Santucci M
Cancer; 1999 Mar; 85(5):1067-76. PubMed ID: 10091790
[TBL] [Abstract][Full Text] [Related]
20. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
